Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2013 · 10-Q
Revenue$6.53M$6.53M−47.9% vs Q3 2012 Net Income-$819.94K-$819.94KN/M vs Q3 2012 EPS Diluted-$0.04-$0.04N/M vs Q3 2012 Operating Income-$1,514,768N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$876,880N/M Margins · derivedOperating margin-23.2%−47.0 pt vs Q3 2012
Net margin-12.6%−27.5 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 6, 2013 · 37 d after period end